Microfluidic hemophilia models using blood from healthy donors
Abstract Background Microfluidic clotting assays permit drug action studies for hemophilia therapeutics under flow. However, limited availability of patient samples and Inter‐donor variability limit the application of such assays, especially with many patients on prophylaxis. Objective To develop ap...
Main Authors: | Xinren Yu, Karen A. Panckeri, Lacramioara Ivanciu, Rodney M. Camire, Carmen H. Coxon, Adam Cuker, Scott L. Diamond |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-01-01
|
Series: | Research and Practice in Thrombosis and Haemostasis |
Subjects: | |
Online Access: | https://doi.org/10.1002/rth2.12286 |
Similar Items
-
Living with a “hemophilia‐free mind” – The new ambition of hemophilia care?
by: Evelien Krumb, et al.
Published: (2021-07-01) -
Thromboelastography and thrombin generation assessments for pediatric severe hemophilia A patients are highly variable and not predictive of clinical phenotypes
by: Natalie Mathews, et al.
Published: (2022-08-01) -
Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors
by: Giancarlo Castaman, et al.
Published: (2024-01-01) -
FIBRIN GLUE DAN APLIKASINYA
by: Agi Harliani S
Published: (2015-08-01) -
Untreated bleeds in people with hemophilia A in a noninterventional study and intrapatient comparison after initiating emicizumab in HAVEN 1–3
by: Michael U. Callaghan, et al.
Published: (2022-08-01)